Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinomaJeffrey D. Krimmel‐Morrison, Rosa Ana Risques, Talayeh Ghezelayagh et al.|Gynecologic Oncology|2019Cited by 23
TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutationsTalayeh Ghezelayagh, Rosa Ana Risques, Jeffrey D. Krimmel‐Morrison et al.|Oncogene|2024Cited by 5
Abstract LB046: Evaluation of<i>TP53</i>mutations in Pap test and blood DNA as novel biomarkers of ovarian cancer riskTalayeh Ghezelayagh, Rosa Ana Risques, Jeanne Fredrickson et al.|Clinical Research (Excluding Clinical Trials)|2021Cited by 0
Evaluation of TP53 mutations in Pap test and blood DNA as novel biomarkers of ovarian cancer riskTalayeh Ghezelayagh, Rosana Risques, Jeanne Fredrickson et al.|Gynecologic Oncology|2021Cited by 0
TP53 mutations in Pap test DNA are a potential biomarker of ovarian cancer risk in high-risk women (226)Talayeh Ghezelayagh, Rosana Risques, Jeanne Fredrickson et al.|Gynecologic Oncology|2022Cited by 0